Freitag, 5. März 2021
Navigation öffnen
Anzeige:
Keytruda Pantumor
Keytruda Pantumor
JOURNAL ONKOLOGIE – STUDIE

STARTRK-2 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Rekrutierend

NCT-Nummer:
NCT02568267

Studienbeginn:
November 2015

Letztes Update:
20.01.2021

Wirkstoff:
Entrectinib

Indikation (Clinical Trials):
Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms, Pancreatic Neoplasms, Sarcoma, Ovarian Neoplasms, Brain Neoplasms, Thyroid Neoplasms, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Thyroid Cancer, Papillary

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Hoffmann-La Roche

Collaborator:
-

Studienleiter

Clinical Trials
Study Director
Hoffmann-La Roche

Kontakt

Reference Study ID Number: GO40782 www.roche.com/about_roche/roche_worldwide.htm
Kontakt:
Phone: 888-662-6728 (U.S. and Canada)
E-Mail: global-roche-genentech-trials@gene.com
» Kontaktdaten anzeigen

Studienlocations (3 von 150)

Charite Universitaetsmedizin Berlin - Campus Charite Mitte ; Charite Comprehensive Cancer Center
10117 Berlin
(Berlin)
GermanyZurückgezogen» Google-Maps
Evang. Lungenklinik Berlin Klinik für Pneumologie
13125 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Carl Gustav Carus TU Dresden
01307 Dresden
(Sachsen)
GermanyRekrutierend» Google-Maps
Asklepios-Fachkliniken Muenchen-Gauting; Onkologie
82131 Gauting
(Bayern)
GermanyZurückgezogen» Google-Maps
Universitaetsmedizin Goettingen; Abteilung Haematologie und Onkologie
37075 Göttingen
(Niedersachsen)
GermanyRekrutierend» Google-Maps
NCT Uniklinikum Heidelberg; Medizinische Onkologie
69120 Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Koeln; Innere Medizin I, Haematologie
50937 Köln
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Western Regional Medical Center at Cancer Treatment Centers of America
85338 Goodyear
United StatesZurückgezogen» Google-Maps
Dignity Health St Joseph's Hospital and Medical Center
85013 Phoenix
United StatesRekrutierend» Google-Maps
Mayo Clinic
85259 Scottsdale
United StatesAktiv, nicht rekrutierend» Google-Maps
City of Hope Cancer Center; Division of Medical Oncology & Experimental Therapeutics
91010 Duarte
United StatesRekrutierend» Google-Maps
Scripps Clinic
92037 La Jolla
United StatesAktiv, nicht rekrutierend» Google-Maps
University of California San Diego Moores Cancer Center; Dept of Lung Cancer
92093 La Jolla
United StatesRekrutierend» Google-Maps
University of Southern California Medical Center
90033 Los Angeles
United StatesRekrutierend» Google-Maps
Univ Of California Irvine College Of Medicine; 300194620
92868 Orange
United StatesAktiv, nicht rekrutierend» Google-Maps
Southern California Kaiser Permanente
92108 San Diego
United StatesRekrutierend» Google-Maps
UCSF Mount Zion Medical Ctr
94115 San Francisco
United StatesAktiv, nicht rekrutierend» Google-Maps
Sarcoma Oncology Center
90403 Santa Monica
United StatesRekrutierend» Google-Maps
University of Colorado Cancer Center
80045 Aurora
United StatesRekrutierend» Google-Maps
Yale University
06510 New Haven
United StatesAktiv, nicht rekrutierend» Google-Maps
Georgetown University Medical Center Lombardi Cancer Center
20007 Washington
United StatesAktiv, nicht rekrutierend» Google-Maps
Florida Cancer Specialists - Sarasota
34232 Sarasota
United StatesAktiv, nicht rekrutierend» Google-Maps
H. Lee Moffitt Cancer Center and Research Inst.
33612 Tampa
United StatesRekrutierend» Google-Maps
Cleveland Clinic Florida
33331 Weston
United StatesZurückgezogen» Google-Maps
University Cancer & Blood Center, LLC; Research
30607 Athens
United StatesAktiv, nicht rekrutierend» Google-Maps
Winship Cancer Institute
30322 Atlanta
United StatesAktiv, nicht rekrutierend» Google-Maps
Southeastern Regional Medical Center, Inc.
30265 Newnan
United StatesAbgeschlossen» Google-Maps
University of Hawaii Cancer Center
96813 Honolulu
United StatesZurückgezogen» Google-Maps
Northwestern University
60611 Chicago
United StatesAktiv, nicht rekrutierend» Google-Maps
Advocate Medical Group - Park Ridge, Luther Lane - Oncology
60068 Park Ridge
United StatesAbgeschlossen» Google-Maps
Midwestern Regional Medical Center
60099 Zion
United StatesRekrutierend» Google-Maps
Weinberg Cancer Institution at Franklin Square
21237 Baltimore
United StatesRekrutierend» Google-Maps
Massachusetts General Hospital
02114 Boston
United StatesRekrutierend» Google-Maps
Beth Israel Deaconess Medical Center
02215 Boston
United StatesAktiv, nicht rekrutierend» Google-Maps
Dana Farber Cancer Institute
02215 Boston
United StatesRekrutierend» Google-Maps
University of Michigan Comprehensive Cancer Center
48109 Ann Arbor
United StatesAktiv, nicht rekrutierend» Google-Maps
Karmanos Cancer Center
48201 Detroit
United StatesAktiv, nicht rekrutierend» Google-Maps
Henry Ford Hospital
48202 Detroit
United StatesAktiv, nicht rekrutierend» Google-Maps
Regents of the University of Minnesota
55455 Minneapolis
United StatesRekrutierend» Google-Maps
Washington University
63128 Saint Louis
United StatesAktiv, nicht rekrutierend» Google-Maps
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
89169 Las Vegas
United StatesRekrutierend» Google-Maps
Dartmouth Hitchcock Medical Center
03756 Lebanon
United StatesZurückgezogen» Google-Maps
North Shore Hem Onc Associates
11733 East Setauket
United StatesAktiv, nicht rekrutierend» Google-Maps
Memorial Sloan Kettering Cancer Center
10065 New York
United StatesRekrutierend» Google-Maps
Levine Cancer Institute
28204 Charlotte
United StatesRekrutierend» Google-Maps
Duke Cancer Institute
27710 Durham
United StatesAktiv, nicht rekrutierend» Google-Maps
OSU, James Cancer Hospital
43210 Columbus
United StatesRekrutierend» Google-Maps
Cancer Treatment Centers of America; Tulsa
74133 Tulsa
United StatesAktiv, nicht rekrutierend» Google-Maps
Providence Portland Medical Center
97213 Portland
United StatesZurückgezogen» Google-Maps
Oregon Health & Science Univ
97239 Portland
United StatesAktiv, nicht rekrutierend» Google-Maps
Cancer Treatment Centers of America - Eastern Regional Medical Center
19124 Philadelphia
United StatesAbgeschlossen» Google-Maps
Mary Crowley Medical Research Center
75230 Dallas
United StatesRekrutierend» Google-Maps
University Hospital Medical Oncology Clinic; Harold C. Simmons Comprehensive Cancer Center
75390 Dallas
United StatesZurückgezogen» Google-Maps
University of Texas MD Anderson Cancer Center
77030 Houston
United StatesRekrutierend» Google-Maps
Baylor Scott & White Health
76502 Temple
United StatesRekrutierend» Google-Maps
University of Utah Hospitals & Clinics
84132 Salt Lake City
United StatesRekrutierend» Google-Maps
Virginia Cancer Specialists, PC
22031 Fairfax
United StatesRekrutierend» Google-Maps
Virginia Oncology Associates - Hampton
23666 Hampton
United StatesRekrutierend» Google-Maps
University of Washington Seattle Cancer Care Alliance
98195 Seattle
United StatesRekrutierend» Google-Maps
Wheaton Franciscan Cancer Care-All Saints
53132 Franklin
United StatesZurückgezogen» Google-Maps
Border Medical Oncology Research Unit
2640 Albury
AustraliaZurückgezogen» Google-Maps
Newcastle Private Hospital
2305 New Lambton Heights
AustraliaAktiv, nicht rekrutierend» Google-Maps
Flinders Medical Centre
5042 Bedford Park
AustraliaRekrutierend» Google-Maps
Beijing Cancer Hospital
100142 Beijing
ChinaNoch nicht rekrutierend» Google-Maps
Beijing Union Hospital
100730 Beijing
ChinaNoch nicht rekrutierend» Google-Maps
Hunan Cancer Hospital
410013 Changsha City
ChinaNoch nicht rekrutierend» Google-Maps
Sichuan Provincial Cancer Hospital
610041 Chengdu
ChinaRekrutierend» Google-Maps
Fujian Provincial Cancer Hospital
350014 Fuzhou City
ChinaNoch nicht rekrutierend» Google-Maps
Cancer Center of Guangzhou Medical University
510000 Guangzhou
ChinaNoch nicht rekrutierend» Google-Maps
Harbin Medical University Cancer Hospital
150081 Harbin
ChinaRekrutierend» Google-Maps
Fudan University Shanghai Cancer Center
200120 Shanghai
ChinaRekrutierend» Google-Maps
Shenzhen People's Hospital
510852 Shenzhen
ChinaNoch nicht rekrutierend» Google-Maps
Tianjin Cancer Hospital
300060 Tianjin
ChinaNoch nicht rekrutierend» Google-Maps
Union Hospital Tongji Medical College Huazhong University of Science and Technology
430023 Wuhan City
ChinaRekrutierend» Google-Maps
Institut de Cancerologie de l Ouest
49055 Angers
FranceRekrutierend» Google-Maps
Institut Bergonie; Oncologie
33076 Bordeaux
FranceRekrutierend» Google-Maps
Centre Oscar Lambret; Chir Cancerologie General
59000 Lille
FranceZurückgezogen» Google-Maps
Centre Leon Berard; Departement Oncologie Medicale
69373 Lyon
FranceRekrutierend» Google-Maps
Hôpital de la Timone; Oncologie Médicale Hématologie & Soins Palliatifs
13385 Marseille cedex 5
FranceRekrutierend» Google-Maps
Hôpital Nord - AP-HM Marseille#; Service d'Oncologie Multidisciplinaire
13015 Marseille
FranceRekrutierend» Google-Maps
Institut de Recherche en Cancérologie de Montpellier
34298 Montpellier cedex 5
FranceRekrutierend» Google-Maps
Hôpital Européen Georges Pompidou; Hématologie Oncologie
75908 Paris cedex 15
FranceZurückgezogen» Google-Maps
Institut Curie; Oncologie Medicale
75231 Paris
FranceRekrutierend» Google-Maps
Institut De Cancerologie De L'ouest - Rene Gauducheau - Biology
44805 Saint Herblain
FranceRekrutierend» Google-Maps
Institut Claudius Regaud; Departement Oncologie Medicale
31059 Toulouse
FranceRekrutierend» Google-Maps
Institut Gustave Roussy; Pathologie Thoracique
94805 Villejuif cedex
FranceRekrutierend» Google-Maps
Hong Kong Integrated Oncology Centre
Hong Kong
Hong KongZurückgezogen» Google-Maps
The Chinese University of Hong Kong
123456 Shatin
Hong KongRekrutierend» Google-Maps
Seconda Università degli Studi di Napoli; Servizio Epato-Gastroenterologia
80131 Napoli
ItalyRekrutierend» Google-Maps
Università Campus Bio-Medico di Roma; Oncologia Medica
128 Roma
ItalyRekrutierend» Google-Maps
Azienda Ospedaliero Universitaria San Martino; Lung Cancer Unit
16132 Genova
ItalyZurückgezogen» Google-Maps
Fondazione IRCCS Istituto Nazionale dei Tumori
20133 Milano
ItalyRekrutierend» Google-Maps
Azienda Socio Sanitaria Territoriale Niguarda (Ospedale Niguarda Ca' Granda); Oncologico -Onc.Falck
20162 Milano
ItalyRekrutierend» Google-Maps
Fondazione del Piemonte per l'Oncologia - IRCCS;Ematologia
10060 Candiolo
ItalyAktiv, nicht rekrutierend» Google-Maps
Azienda Ospedaliero-Universitaria S.Luigi Gonzaga; SSD Oncologia Polmonare
10043 Orbassano
ItalyZurückgezogen» Google-Maps
A.O Città della Salute e della Scienza di Torino; Colorectal Cancer Unit (CRCU) - SSCVD
10126 Torino
ItalyZurückgezogen» Google-Maps
Azienda Ospedaliero - Universitaria Pisana U.O. Oncologia Medica 2 Universitaria - Polo Oncologico
56126 Pisa
ItalyRekrutierend» Google-Maps
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia ; S.C. Oncologia Medica
6132 Perugia
ItalyRekrutierend» Google-Maps
IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II
35128 Padova
ItalyRekrutierend» Google-Maps
Aichi Cancer Center Hospital; Respiratory Medicine
464-8681 Aichi
JapanRekrutierend» Google-Maps
NHO Shikoku Cancer Center; Dept of Respiratory Medicine
791-0280 Ehime
JapanRekrutierend» Google-Maps
Hyogo Cancer Center, Dept of Respiratory Medicine
673-8558 Hyogo
JapanRekrutierend» Google-Maps
National Cancer Center Hospital; Dept of Respiratory Medicine
277-8577 Kashiwa-shi
JapanRekrutierend» Google-Maps
Miyagi Cancer Center; Respiratory Medicine
981-1293 Miyagi
JapanRekrutierend» Google-Maps
Niigata Cancer Center Hospital; Internal Medicine
951-8566 Niigata
JapanRekrutierend» Google-Maps
OSAKA CITY GENERAL HOSPITAL;Medical Oncology
534-0021 Osaka
JapanRekrutierend» Google-Maps
Kindai University Hospital; Medical Oncology
589-8511 Osaka
JapanRekrutierend» Google-Maps
Shizuoka Cancer Center; Respiratory Internal Medicine
411-8777 Shizuoka
JapanRekrutierend» Google-Maps
Chungbuk National University Hospital
28644 Cheongju-si
Korea, Republic ofZurückgezogen» Google-Maps
Samsung Medical Center
(0)6351 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Severance Hospital, Yonsei University Health System
03722 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Asan Medical Center.
138-736 Seoul
Korea, Republic ofRekrutierend» Google-Maps
NKI The Netherlands Cancer Institute
1066 CX Amsterdam
NetherlandsRekrutierend» Google-Maps
Leids Universitair Medisch Centrum
2333 ZA Leiden
NetherlandsRekrutierend» Google-Maps
Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii
80-214 Gdańsk
PolandRekrutierend» Google-Maps
Centrum Onkologii-Instytut im.M.Sklodowskiej Curie; Dept of Nuclear Med. and Endocrine Oncology
44-101 Gliwice
PolandRekrutierend» Google-Maps
Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy; Dept of Pulmonology & subdiv. of oncology
05-400 Otwock
PolandZurückgezogen» Google-Maps
Szpital Kliniczny Przemienienia Panskiego Uni. Medycznego im. Karola Marcinkowskiego; Chemotherapy
60-569 Poznań
PolandRekrutierend» Google-Maps
Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Klinika Nowotworow Ukladu Chlonnego
02-781 Warszawa
PolandRekrutierend» Google-Maps
National University Hospital; Haematology/Oncology
119074 Singapore
SingaporeRekrutierend» Google-Maps
Centro Nacional de Investigaciones Oncológicas(CNIO); Gastrointestinal Cancer Clinical Research Unit
28942 Fuenlabrada
SpainZurückgezogen» Google-Maps
Hospital Universitari Vall dHebron; Oncology
08035 Barcelona
SpainRekrutierend» Google-Maps
Hospital Universitario de La Princesa; Servicio de Oncologia
28006 Madrid
SpainZurückgezogen» Google-Maps
Hospital Universitario Ramon y Cajal; Servicio de Farmacia
28034 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
28040 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario 12 de Octubre; Servicio de Oncologia
28041 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario La Paz; Servicio de Oncologia
28046 Madrid
SpainRekrutierend» Google-Maps
START Madrid. Centro Integral Oncologico Clara Campal; Unidad de Fase I-Oncologica
28050 Madrid
SpainRekrutierend» Google-Maps
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia
29010 Malaga
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen del Rocio; Servicio de Oncologia
41013 Sevilla
SpainRekrutierend» Google-Maps
Changhua Christian Hospital
500 Chang Hua
TaiwanZurückgezogen» Google-Maps
Taichung Veterans General Hospital
407 Taichung
TaiwanZurückgezogen» Google-Maps
National Cheng Kung University Hospital
70457 Tainan
TaiwanRekrutierend» Google-Maps
Taipei Veterans General Hospital
11217 Taipei City
TaiwanRekrutierend» Google-Maps
National Taiwan University Hospital
10002 Taipei
TaiwanRekrutierend» Google-Maps
Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
CB2 0QQ Cambridge
United KingdomRekrutierend» Google-Maps
Sarah Cannon Research Institute
W1G 6AD London
United KingdomRekrutierend» Google-Maps
Christie Hospital Nhs Trust; Medical Oncology
M2O 4BX Manchester
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for

the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene

fusion. Patients will be assigned to different baskets according to tumor type and gene

fusion.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically- or cytologically-confirmed diagnosis of locally advanced or metastatic

solid tumor that harbors an NTRK1/2/3, ROS1, or ALK gene rearrangement

- Note: Patients diagnosed with anaplastic large cell lymphoma (ALCL) harboring a gene

rearrangement of interest may be eligible provided they meet all other

inclusion/exclusion criteria

- For patients enrolled via local molecular testing, an archival or fresh tumor tissue

(unless medically contraindicated) is required to be submitted for independent central

molecular testing at Ignyta's CLIA laboratory post-enrollment

- Measurable or evaluable disease

- Patients with CNS involvement, including leptomeningeal carcinomatosis, which is

either asymptomatic or previously-treated and controlled, are allowed

- Prior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1,

or ALK inhibitors in patients who have tumors that harbor those respective gene

rearrangements)

- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged

NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are

prohibited.

- At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior

chemotherapy or small molecule targeted therapy

- At least 4 weeks must have elapsed since completion of antibody-directed therapy

- Prior radiotherapy is allowed if more than 14 days have elapsed since the end of

treatment

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 and minimum life

expectancy of 4 weeks

- Adequate organ function as defined per protocol

- Ability to swallow entrectinib intact

- Other protocol specified criteria

Exclusion Criteria:

- Current participation in another therapeutic clinical trial

- Prior treatment with approved or investigational Trk, ROS1, or ALK inhibitors in

patients who have tumors that harbor those respective gene rearrangements

- Note: prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged

NSCLC patients presenting with CNS-only progression. Other ALK inhibitors are

prohibited.

- History of other previous cancer that would interfere with the determination of safety

or efficacy

- Familial or personal history of congenital bone disorders, bone metabolism alterations

or osteopenia

- Incomplete recovery from any surgery

- History of recent (within the past 3 months) symptomatic congestive heart failure or

ejection fraction ≤50% observed during screening for the study

- History of non-pharmacologically induced prolonged QTc interval

- History of additional risk factors for torsades de pointes

- Peripheral neuropathy Grade ≥ 2

- Known active infections

- Active gastrointestinal disease or other malabsorption syndromes

- Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase

inhibitor-induced pneumonitis

- Other protocol specified criteria

Studien-Rationale

Primary outcome:

1. Objective Response Rate (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1



Secondary outcome:

1. Duration of Response (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1

2. Time to Response (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1

3. Clinical Benefit Rate (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RECIST v1.1

4. Intracranial Tumor Response (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable

5. CNS Progression-free Survival (Time Frame - Approximately 24 months):
Assessed by blinded independent central review (BICR) using RANO or RANO-BM, as applicable

6. Progression-free Survival (Time Frame - Approximately 30 months):
Assessed by Kaplan-Meier method

7. Overall Survival (Time Frame - Approximately 36 months):
Assessed by Kaplan-Meier method

8. Population PK (Time Frame - Approximately 24 months):
Assessed by Kaplan-Meier method

9. Adverse Events (Time Frame - Approximately 36 months):
Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities, graded by the NCI CTCAE

10. Quality of Life (Time Frame - Approximately 24 months):
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30) and the Euro-QoL Group EQ-5D. NSCLC and mCRC patients will complete the lung cancer and colorectal cancer specific modules, QLQ-LC13 and QLQ-CR29, respectively

11. Bone Growth and Bone Mineral Density (Time Frame - Approximately 30 months):
Assessed with DHA scans

12. Bone Biomarkers (Time Frame - Approximately 30 months):
Measured by blood

Studien-Arme

  • Experimental: NTRK1/2/3-rearranged NSCLC
    Oral entrectinib (RXDX-101)
  • Experimental: ROS1-rearranged NSCLC
    Oral entrectinib (RXDX-101)
  • Experimental: ALK- or ROS1-rearranged NSCLC
    with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.) Oral entrectinib (RXDX-101)
  • Experimental: NTRK/1/2/3-rearranged mCRC
    Oral entrectinib (RXDX-101)
  • Experimental: ROS1-rearranged mCRC
    Oral entrectinib (RXDX-101)
  • Experimental: ALK-rearranged mCRC
    Oral entrectinib (RXDX-101)
  • Experimental: NTRK1/2/3-rearranged other solid tumor
    Oral entrectinib (RXDX-101)
  • Experimental: ROS1-rearranged other solid tumor
    Oral entrectinib (RXDX-101)
  • Experimental: ALK-rearranged other solid tumor
    Oral entrectinib (RXDX-101)

Geprüfte Regime

  • Entrectinib (RXDX-101):
    TrkA/B/C, ROS1, and ALK inhibitor

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Bauchspeicheldrüsenkrebs: Die Bauchspeicheldrüse, das unbekannte Organ

Die Bauchspeicheldrüse (griech.: Pankreas) ist eine der größten Drüsen des Menschen. Dennoch ist nur wenigen bekannt, wo sie sich befindet und welche Funktionen sie übernimmt. Die Bauchspeicheldrüse ist ein keilförmiges Organ, ungefähr so groß wie eine Hand: ein bis zwei Zentimeter dick und etwa 15 Zentimeter lang. Sie liegt mitten im Oberbauch hinter dem Magen und vor der Wirbelsäule. Mit ihrem sich verjüngenden Ende – dem...

Helfen und sich helfen lassen - neues Informationsblatt vom Krebsinformationsdienst des Deutschen Krebsfoschungszentrums

Helfen und sich helfen lassen - neues Informationsblatt vom Krebsinformationsdienst des Deutschen Krebsfoschungszentrums
Alexander Raths / Fotolia.com

Die Diagnose Krebs ist für die meisten Menschen ein Schock. Das gilt auch für Partner, Familienangehörige und Freunde von Krebspatienten. Neben der Sorge und dem Impuls, den anderen zu unterstützen, fühlen sich viele in dieser Situation zunächst unsicher und überfordert. Die Angst, im Miteinander etwas falsch zu machen, ist groß. Zur Unterstützung von Angehörigen und Freunden hat der Krebsinformationsdienst des Deutschen...

Urologen starten Themenwoche Hodenkrebs vom 27. bis 31. März 2017

Urologen starten Themenwoche Hodenkrebs vom 27. bis 31. März 2017
© Paolese / Fotolia.com

Deutschlands Urologen gehen neue Wege in der Öffentlichkeitsarbeit: Mit der Einführung der „Urologischen Themenwochen“ baut die Deutsche Gesellschaft für Urologie e.V. (DGU) ihr Engagement in der medizinischen Aufklärung der Bevölkerung erneut aus: Den Anfang macht die Urologische Themenwoche Hodenkrebs vom 27. bis 31. März 2017. Mit zielgruppengerecht aufbereiteten Informationen wollen Urologinnen und Urologen männliche Heranwachsende und junge...